-5%
Liglimet is indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus, when treatment with both Linagliptin and Metformin is appropriate.
Linagliptin
DPP-4 inhibitor: Prevents degradation of incretin hormones (GLP-1 and GIP).
Enhances glucose-dependent insulin secretion.
Reduces glucagon release from α-cells.
Improves blood glucose without causing hypoglycemia.
Metformin Hydrochloride
A biguanide class oral antidiabetic.
Reduces hepatic glucose production, slows glucose absorption, and enhances peripheral glucose uptake.
Does not cause hypoglycemia when used alone.